Ryan Cross
Senior Correspondent at Endpoints News
Senior Science Correspondent for @Endpts covering biotech, drug discovery, gene editing, RNA, and more. Formerly at Boston Globe and C&EN. Threads: ryancross
Articles
-
1 week ago |
endpts.com | Ryan Cross
Myeloid Therapeutics, a company developing in vivo cell therapies for cancer as well as a novel gene editing technology, has restructured to focus on its …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
2 weeks ago |
endpts.com | Ryan Cross
Two Boston scientists say they have developed a new gene editing tool based on mysterious “jumping genes” known as retrotransposons, which can copy and paste …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
2 weeks ago |
endpts.com | Ryan Cross
Alzheon’s controversial, decade-long bet that a failed Alzheimer’s drug could offer bigger benefits to a subset of patients at the highest risk for the disease …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
2 weeks ago |
endpts.com | Ryan Cross
Gene editing pioneer David Liu was awarded one of three Breakthrough Prizes in Life Sciences for his invention of base and prime editing. The two …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
3 weeks ago |
endpts.com | Ryan Cross
A Shanghai-based startup quietly became the first in the world to start a clinical trial for a circular RNA therapy, a cutting-edge form of genetic …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 4K
- Tweets
- 2K
- DMs Open
- Yes
FDA announced plans to reduce or replace animal testing requirements for some drugs, including antibodies. The suggested alternatives are organoids, organ-on-a-chip tech, or AI/computer simulations. Good idea? Or bad? Biotech folks, what do you think? https://t.co/skHr7Azsko
Alzheon’s amyloid-targeting pill fails another Alzheimer’s Phase 3, this time in people carrying two copies of the APOE4 gene that dramatically raises the risk of dementia. Read more in my story for @endpts - https://t.co/kGHAFUGHmI
I talked to base and prime editing inventor @davidrliu about academic science under pressure, Peter Marks' departure from the FDA, and his upcoming work on “disease-agnostic” gene editing. Read more in my Q&A for @endpts - https://t.co/99BQaxxun5
